Core Insights - embecta Corp. has expanded its partnership with Direct Relief to enhance access to diabetes care for underserved communities in the U.S. and globally [1][2][3] Company Overview - embecta was spun off from Becton, Dickinson and Company in 2022, acquiring BD-branded pen needles and insulin syringes [2] - The company has updated its packaging in North America from the BD brand to the embecta brand in 2025 [2] - Since becoming independent, embecta has focused on empowering individuals with diabetes and ensuring access to necessary supplies [3] Partnership Details - embecta has donated approximately 15 million units of pen needles and insulin syringes to Direct Relief, marking its largest humanitarian partnership since independence [2] - The partnership aims to provide essential diabetes management supplies to uninsured and low-income patients through Direct Relief's Safety Net Support Program [4][5] - Direct Relief collaborates with over 1,600 community health centers and clinics, serving more than 36 million patients, including a significant portion of the uninsured population in the U.S. [4] Global Impact - The partnership supports Direct Relief's Life for a Child program, which provides diabetes care to over 53,000 children and young people in 45 countries [6] - embecta's donations also support diabetes care in crisis-affected regions, including a recent donation of 2.7 million insulin needles and syringes for a campaign in Sudan [8][7] Educational Initiatives - embecta supports diabetes education camps through Direct Relief, providing essential supplies to help children and young adults learn diabetes management skills [10] Emergency Response - The partnership includes emergency response capabilities, with a recent grant of $25,000 from embecta to support disaster relief efforts in Texas [11] Industry Context - Over 537 million people globally live with diabetes, with projections reaching 783 million by 2045; in the U.S., approximately 38 million individuals are affected [12] - Access to affordable diabetes care remains a critical challenge, particularly for uninsured and underinsured populations [12]